Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA3 | P07451 | 3/20 | 0.53 |
| ▸ | CA4 | P22748 | 3/20 | 0.53 |
| ▸ | CA6 | P23280 | 3/20 | 0.53 |
| ▸ | CA5A | P35218 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258295 | 1.00 | KDM4E (0.53) | KDM4EHSD17B10MAPK1CA12CA1 | |
| SCHEMBL30842600 | 0.86 | GABBR2 (0.44) | KDM4EHSD17B10MAPK1CA12CA1 | |
| SCHEMBL584807 | 0.86 | GPR183 (0.53) | KDM4EHSD17B10MAPK1CA12CA1 | |
| SCHEMBL584806 | 0.86 | GPR183 (0.53) | KDM4EHSD17B10MAPK1CA12CA1 | |
| SCHEMBL22046680 | 0.84 | MAOA (0.43) | CYP3A4BACE1CYP2C9 | |
| SCHEMBL407484 | 0.83 | KDM4E (0.58) | KDM4EHSD17B10MAPK1CA12CA1 | |
| SCHEMBL111230 | 0.83 | KDM4E (0.58) | KDM4EHSD17B10MAPK1CA12CA1 | |
| SCHEMBL407485 | 0.83 | KDM4E (0.58) | KDM4EHSD17B10MAPK1CA12CA1 | |
| SCHEMBL584596 | 0.83 | KDM4E (0.58) | KDM4EHSD17B10MAPK1CA12CA1 | |
| SCHEMBL29389045 | 0.83 | KDM4E (0.58) | KDM4EHSD17B10MAPK1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017646-B2 | e.g. 1-{3-[3-(3,4-dimethoxyphenyl)propoxy]propyl}pyrrolidine; neurodegenerative disorders, antidepressant, antidiabetic, hypotensive agent, cognition activator; | BIOPROJET (FR) | 2011-09-13 | — | — | US | disclosed |
| US-7879911-B2 | 2-(4-Fluorophenoxy-N-hydroxyacetamide where the \"oxy\" can also be sulfonyl, sulfamyl or sulfinyl; enzyme inhibitors of the \"lethal factor\" enzyme released by bacillus anthraci that splits an essential peptide needed by mammals for signal transmission; antidotes; biological warfare | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-01 | — | — | US | disclosed |
| WO-2009008905-A1 | HYDROXAMIC ACID DERIVATIVES OF PHENOXY-ACETIC ACIDS AND ANALOGS USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARMA, LLC. | 2009-01-15 | — | — | WO | disclosed |
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080182876-A1 | Histamine H3-Receptor Ligands and Their Therapeutic Application | BIOPROJET (FR) | 2008-07-31 | — | — | US | disclosed |
| EP-1874747-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117611-A1 | HISTAMINE H3-RECEPT0R LIGANDS AND THEIR THERAPEUTIC APPLICATION | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
| EP-1717233-A1 | Histamine H3-receptor ligands and their therapeutic application | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
| EP-0560080-B1 | Electrophotographic toner | HODOGAYA CHEMICAL CO LTD (JP) | 1998-01-14 | — | — | EP | disclosed |
| US-5346794-A | Arylacrylic acid | HODOGAYA CHEMICAL CO., LTD. (JP) | 1994-09-13 | — | — | US | disclosed |
| EP-0560080-A1 | Electrophotographic toner | HODOGAYA CHEMICAL CO., LTD. (JP) | 1993-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | ANTXR2, HAAO, PAOX | KDM4E 1261/4885HSD17B10 461/4885MAPK1 1069/4885 |
| US-20080182876-A1 | Histamine H3-Receptor Ligands and Their Therapeutic Application | HRH3, HRH4, HRH1 | KDM4E 1619/4885HSD17B10 2176/4885MAPK1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.